8-K: Caribou's CAR-T Therapies Show Strong Clinical Data

Caribou Biosciences announced positive preliminary financial results and compelling clinical data from its ANTLER and CaMMouflage Phase 1 trials for allogeneic CAR-T cell therapies vispa-cel and CB-011.

Summary

• Caribou Biosciences reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $159.2 million as of September 30, 2025.
• The ANTLER Phase 1 trial for vispa-cel in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) showed an 82% overall response rate (ORR) and 64% complete response (CR) rate in the 22-patient confirmatory cohort, with 51% progression-free survival (PFS) at 12 months.
• An optimized vispa-cel product profile cohort (N=35) demonstrated an 86% ORR, 63% CR rate, and 53% PFS at 12 months, with one patient in complete response at 3 years post-infusion.
• Vispa-cel was generally well tolerated, with no cases of graft-versus-host disease (GvHD) or grade 3 or greater immune effector cell-associated neurotoxicity syndrome (ICANS) in the confirmatory and optimized cohorts.
• The company plans a randomized, controlled pivotal Phase 3 trial for vispa-cel in second-line (2L) large B cell lymphoma (LBCL) CD19-naive patients, expecting to enroll approximately 250 patients, following FDA recommendations.
• The CaMMouflage Phase 1 trial for CB-011 in relapsed or refractory multiple myeloma (r/r MM) showed a 92% ORR and 75% CR/stringent CR (sCR) rate in the 12-patient BCMA-naive cohort treated at the recommended dose for expansion (RDE).
• 91% of evaluable patients in the CB-011 RDE cohort achieved minimal residual disease (MRD) negativity (10^-5), with 7 of 12 patients remaining on study in very good partial response (VGPR) or better at 6 months or longer.
• CB-011 had a manageable safety profile with no GvHD, immune effector cell-associated enterocolitis (IEC-EC), parkinsonism, or cranial nerve palsies observed at any dose level.
• The company plans to initiate dose expansion for the CaMMouflage trial before the end of 2025 and report data in 2026.

Sentiment

Score: 8

Explanation: The clinical data for both vispa-cel and CB-011 are highly positive, demonstrating efficacy and safety profiles that are competitive with or superior to existing therapies, particularly for allogeneic, off-the-shelf options. The clear regulatory path for vispa-cel and planned advancement of CB-011 are strong indicators of progress. The preliminary cash balance provides some runway, though future capital needs are acknowledged, which is typical for a clinical-stage biotech.

Positives

• Vispa-cel's efficacy and durability are on par with approved autologous CAR-T cell therapies, with an 86% ORR, 63% CR rate, and 53% 12-month PFS in the optimized profile cohort.
• Vispa-cel demonstrated a generally well-tolerated safety profile, allowing for potential outpatient administration, with no GvHD or grade 3+ ICANS and less than 5% grade 3+ cytokine release syndrome (CRS) in key cohorts.
• Vispa-cel has received Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations from the FDA for r/r B-NHL.
• CB-011 achieved deep and durable responses in heavily pretreated r/r MM patients, with a 92% ORR, 75% CR/sCR rate, and 91% MRD negativity in the BCMA-naive RDE cohort.
• CB-011 exhibited a manageable safety profile, with no GvHD, IEC-EC, parkinsonism, or cranial nerve palsies observed at any dose level, and rapid immune recovery.
• CB-011 has received Fast Track and Orphan Drug designations from the FDA for r/r MM.
• The FDA has provided clear guidance for a randomized, controlled pivotal Phase 3 trial for vispa-cel, which the company believes provides a straightforward regulatory path to full approval.
• The company's allogeneic CAR-T cell therapies offer advantages over autologous treatments, including broad patient access, shorter time to treatment, and significantly lower manufacturing costs (potential for 96% lower COGS for vispa-cel and 80% lower for CB-011 at launch).

Negatives

• Preliminary financial results for cash, cash equivalents, and marketable securities are unaudited and subject to significant adjustments during the quarter-end financial close process.
• One vispa-cel-related grade 5 immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) occurred on day 25 post-infusion in the ANTLER trial.
• Enrollment in the 3L+ LBCL patient cohort with prior CD19-targeted therapy in the ANTLER trial has been paused to focus on CD19-naive patients.
• Notable adverse events in the CB-011 RDE cohort included one CB-011-related grade 5 immune effector cell-associated hematotoxicity (ICAHT) on day 90 and one CB-011-related grade 4 Guillain-Barr Syndrome on day 129 (resolving).

Risks

• Risks inherent in the development of allogeneic CAR-T cell therapy products.
• Uncertainties related to the initiation, cost, timing, progress, and results of current and future clinical trials.
• The risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of CAR-T cell therapy product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available.
• The risk that different conclusions or considerations are reached once additional data have been received and fully evaluated.
• The ability to obtain key regulatory input and approvals, as the FDA may recommend or request additional requirements in future discussions.
• Risks related to the company's limited operating history, history of net operating losses, and financial position.
• The need for and ability to raise additional capital as needed to fund operations and product candidate development, including fully funding the pivotal Phase 3 clinical trial for vispa-cel, and the potential dilution to stockholders resulting therefrom.
• Risks related to the ability to establish and/or maintain intellectual property rights covering product candidates and genome-editing technology.
• Risks of third parties asserting that product candidates infringe their patents.
• Risks related to developments of competitors and the industry.
• Risks related to reliance on third parties to conduct clinical trials and manufacture product candidates.
• Risks caused by public health crises or geopolitical events on the business and operations.
• Risks related to the volatility of the stock price and potential failure to meet Nasdaq listing requirements.

Future Outlook

The company plans to conduct a randomized, controlled pivotal Phase 3 trial for vispa-cel in 2L LBCL CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy, expecting to evaluate approximately 250 patients. The trial design will be further refined through continued engagement with the FDA. For CB-011, the company intends to initiate dose expansion of the CaMMouflage Phase 1 clinical trial before the end of 2025 and report dose expansion data, along with longer follow-up on dose escalation data, in 2026.

Management Comments

• Mehdi Hamadani, MD, Medical College of Wisconsin: "This clinical dataset demonstrates vispa-cel's efficacy and durability are comparable to autologous CAR-T therapies, yet its off-the-shelf availability and favorable tolerability profile make it well suited for outpatient administration at both large academic centers and sophisticated community hospitals. This combination of robust clinical activity and accessibility could significantly broaden patient access to transformative CAR-T cell treatments, particularly for those who cannot wait or are ineligible for transplantation or autologous CAR-T cell therapies."
• Rachel Haurwitz, PhD, President and CEO, Caribou Biosciences: "We believe that with these results, Caribou has achieved what the field has long sought – strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use."
• Rachel Haurwitz, PhD, President and CEO, Caribou Biosciences: "This milestone positions vispa-cel as a potentially best-in-class allogeneic CAR-T cell therapy for patients with large B cell lymphoma. We believe we have a straightforward regulatory path toward full registration by following the FDA’s recommendation for a randomized, controlled phase 3 trial in second-line large B cell lymphoma, and we plan to refine our pivotal trial design in the coming months through continued engagement with the FDA."
• Adriana Rossi, MD, Mount Sinai: "I believe the promising responses we are seeing with CB-011 combined with the off-the-shelf nature of this therapy could represent a paradigm shift for patients with relapsed or refractory multiple myeloma. I am excited about the potential this holds for the large number of multiple myeloma patients who simply cannot wait for autologous CAR-T manufacturing and prefer a single dose approach."
• Rachel Haurwitz, PhD, President and CEO, Caribou Biosciences: "We are very encouraged by the compelling results from the CaMMouflage phase 1 trial, which demonstrate that CB-011 is delivering deep, durable responses in high-risk, heavily pretreated multiple myeloma patients with a manageable safety profile. These data establish CB-011’s potential to be a best-in-class allogeneic CAR-T cell therapy that could expand access and bring meaningful benefit to patients who urgently need a readily available, single-dose option."

Industry Context

Caribou Biosciences is advancing allogeneic (off-the-shelf) CAR-T cell therapies, which aim to overcome the significant limitations of current autologous CAR-T therapies, such as lengthy manufacturing times, high costs, and restricted patient access. The company's approach, utilizing CRISPR genome-editing for enhanced activity and immune cloaking, positions its candidates (vispa-cel and CB-011) to potentially offer broader accessibility, rapid treatment, and lower manufacturing costs compared to existing autologous CAR-T options and potentially superior efficacy/safety profiles compared to bispecific antibodies in their respective indications.

Comparison to Industry Standards

• Vispa-cel's efficacy (ORR 82-86%, CR 63-64%, 12-month PFS 51-53%) in LBCL is reported to be on par with approved autologous CAR-T cell therapies like Axi-cel (ZUMA-7: ORR 83%, CR 65%, 12-month PFS 54%) and Liso-cel (TRANSFORM: ORR 86%, CR 66%, 12-month PFS 52%).
• Vispa-cel's safety profile, with no GvHD or grade 3+ ICANS and low rates of grade 3+ CRS (<5%), is presented as enabling outpatient administration, a significant advantage over many autologous CAR-T therapies.
• The company projects vispa-cel to have potentially 96% lower Cost of Goods Sold (COGS) than current autologous CAR-T cell therapies.
• CB-011's efficacy in r/r MM (ORR 92%, CR/sCR 75%, MRD negativity 91%) significantly outperforms reported bispecific antibody therapies such as Teclistamab (ORR 63%, CR 40%, MRD 27%) and Elranatamab (ORR 61%, CR 35%).
• CB-011 demonstrates lower rates of Grade 3-4 infections (17% at RDE) compared to bispecifics (e.g., Teclistamab 45%, Elranatamab 40%, Linvoseltamab 36%), and offers a single-dose treatment regimen versus repeat dosing for bispecifics.
• CB-011's efficacy is competitive with autologous anti-BCMA CAR-T cell therapies like Abecma (ORR 71%, CR 39%) and Carvykti (ORR 85%, CR 73%), and anito-cel (ORR 97%, CR 62%), while showing lower rates of Grade 3+ CRS (8%) and neurotoxicity (0%) compared to some autologous options.
• The company projects CB-011 to have potential COGS approximately 80% lower at launch than current autologous CAR-T cell therapies.

Stakeholder Impact

• **Patients**: Potential for significantly improved access to CAR-T cell therapies due to off-the-shelf availability, shorter treatment times, and a safety profile that may allow for outpatient administration. This could benefit patients ineligible for or unable to wait for autologous CAR-T therapies.
• **Shareholders**: The strong positive clinical data and clear regulatory path for vispa-cel, along with promising CB-011 results, are highly likely to increase investor confidence and potentially drive share price appreciation. However, the explicit mention of future capital needs introduces potential dilution risk.
• **Healthcare Providers**: The off-the-shelf nature and manageable safety profiles of these therapies could simplify logistics, reduce the burden on specialized centers, and enable broader adoption in community settings, expanding treatment options for patients.
• **Competitors**: The promising results for allogeneic CAR-T therapies could intensify competition in the cellular immunotherapy space, particularly for companies developing autologous CAR-T and bispecific antibody treatments.

Next Steps

• Further refine the pivotal Phase 3 clinical trial design for vispa-cel through continued engagement with the FDA prior to trial initiation.
• Initiate dose expansion of the CaMMouflage Phase 1 clinical trial for CB-011 before the end of 2025.
• Report CaMMouflage dose expansion data, along with longer follow-up on dose escalation data, in 2026.
• Host a live webcast on November 3, 2025, at 8:00 a.m. Eastern Time to discuss the clinical developments.

Key Dates

Recommendation

The clinical data presented for both vispa-cel and CB-011 are exceptionally strong, demonstrating efficacy and durability on par with or superior to current autologous CAR-T and bispecific therapies, while offering the significant advantages of an off-the-shelf, allogeneic product. The FDA's recommendation for a randomized Phase 3 trial for vispa-cel provides a clear and accelerated regulatory pathway, significantly de-risking the program. CB-011's deep, durable responses and manageable safety profile in heavily pretreated multiple myeloma patients are highly compelling. While the company will require additional capital, the robust clinical progress and potential to address major unmet needs in large markets position Caribou Biosciences for substantial future growth and market penetration. This represents a significant de-risking event for a clinical-stage biotech, warranting a strong buy recommendation.

Keywords

CRISPR, CAR-T, Allogeneic, Vispa-cel, CB-011, Lymphoma, Multiple Myeloma, Oncology, Biopharmaceutical, Clinical Trial, Genome Editing, FDA, RMAT, Fast Track